NEW YORK (GenomeWeb News) – Diaxonhit today announced an agreement with Boehringer Ingelheim to discover and characterize novel splice variants that potentially could be therapeutic targets for oncology.

Paris-based Diaxonhit will use its SpliceArray discovery platform to identify potential targets and then build a database of specific splice variants. Boehringer Ingelheim has the option to buy the rights to research, develop, and commercialize any targets discovered by Diaxonhit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.

Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.

Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.